Targeted Strategies for Today's Evolving Markets

MissionIR Blog

FluoroPharma Medical, Inc. (FPMI) Appoints Mr. Thijs Spoor as Chief Executive Officer and Director

FluoroPharma, an independent privately held biopharmaceutical company engaged in discovery and development of imaging radiopharmaceuticals for use in cardiology and Alzheimer’s disease, announced today the appointment of Thijs Spoor as the new CEO in conjunction with his appointment to its Board of Directors. Mr. Spoor has 15 years of international experience in the medical industry across a variety of roles including Regulatory Affairs, New Product Development and as the Global Brand Head for Nuclear Cardiology at (Amersham) GE Healthcare and most recently as the CFO of Sunstone BioSciences. He also spent 4 years on Wall Street at J.P. Morgan and Credit Suisse where he covered biotechnology and medical device stocks. He trained as a nuclear pharmacist and holds a Pharmacy degree from the University of Toronto and an MBA from Columbia University.

Mr. Spoor joined the Board of Directors consisting of Dr. David Elmaleh, Chairman and Scientific founder, Dr. Peter Conti and Mr. Walter Witoshkin. “I am pleased to welcome Mr. Spoor to our Board of Directors,” said Dr. Conti. “He brings substantial industry and capital markets experience which will be an asset to the team as we continue to work toward developing diagnostic agents for discrete unmet medical needs.”

“Our Board and our Company got stronger today,” said Dr. David Elmaleh Founder, Chairman and Chief Scientific Officer of FluoroPharma. “As we turn to the rest of 2010 and beyond, we are focused on creating investor value by furthering the field of molecular imaging. Mr. Spoor will help us achieve our goals by leveraging his experience and proven track records of success. I’m excited to begin working with him on the future of our Company.”

Mr. Spoor had previously been an advisor to the company and joined the company effective September 3rd. “I am excited to help take Fluoropharma’s unique portfolio closer to becoming an integral portion of patient care” said Spoor. “The company’s products address specific unmet medical needs which have long been pursued in the field of molecular imaging.”

Let us hear your thoughts below:

This entry was posted in FluoroPharma Medical Inc. FPMI. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *